Iclusig approved for rare leukemias

Iclusig approved for rare leukemias

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

The drug was sanctioned for adults with (CML) and -positive (Ph+ ALL), the FDA said in a news release.

Iclusig blocks the effects of proteins that promote development of cancer cells, the agency said. The drug was granted accelerated approval following a single study of 449 people with either CML or Ph+ ALL.

The product's label will include a boxed warning that users are at heightened risk of blood clots and liver poisoning. More common but less serious clinical side effects included high blood pressure, rash, abdominal pain, fatigue, headache, dry skin, constipation, fever, joint pain, and nausea.

Iclusig is marketed by Ariad Pharmaceuticals, based in Cambridge, Mass.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Marqibo approved for ph- acute lymphoblastic leukemia

Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia ...

Marqibo approved for rare leukemia

Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative ...

Synribo approved to treat rare leukemia

Oct 26, 2012

(HealthDay)—Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).

Clinical trial delivers good results in leukemia patients

Nov 30, 2012

Huntsman Cancer Institute (HCI) researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard ...

Recommended for you

Video: Is that double mastectomy really necessary?

Oct 24, 2014

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments